Endocannabinoids in Reward
Key facts
- Who runs it
- Medical University of South Carolina
- Where
- Charleston, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 78 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 31 Jul 2031
- Type of study
- Interventional, 2 groups
- Treatments tested
- Dronabinol
- Placebo
- Record updated
- 5 October 2026
Who can take part
- Age
- 21 years to 45 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Able and willing to provide informed consent
- Age 21-45
- Meet DSM-5 criteria for CUD
- Report cannabis use ≥4 days/week on average in the last 30 days at screening
- Provide a THC-positive urine sample at screening
- BMI between 18-30 kg/m2
- Regular menstrual cycle (females only)
- Willing to use non-hormonal birth control for the duration of study participation (females only)
Who cannot take part
- Urinalysis results indicative of recent drug use other than cannabis
- Current use of any psychotropic medication or over-the-counter supplements deemed by the investigator to have the potential to interfere with study outcomes
- MRI contraindications (e.g., metallic implants, claustrophobia)
- Meet DSM-5 criteria for any lifetime psychotic or bipolar disorder
- Meet DSM-5 criteria for any current psychiatric disorder other than nicotine or caffeine use disorder, mild alcohol use disorder, CUD, or ADHD
- Significant history of nausea associated with the use of cannabis and/or THC
- History of cardiac or seizure disorders
- Allergy to sesame oil
- Current treatment-seeking for CUD or other SUDs
- Females who are pregnant, nursing, or planning to become pregnant
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 45 years old?
Where in United States
- Medical University of South CarolinaCharleston, United StatesContact: Erin Martin, Ph.D.Taking people
About the trial
What the trial wants to find out
This study will examine sex differences in the effects of cannabis in people that regularly use it. Men and women that use cannabis at least 4 days a week will participate in a study involving 3 in-person visits. The first visit will be used to determine eligibility for the study. The other two visits will last 7 hours each and take place at least two days apart. Visits include administration of either THC, the chemical responsible for many of the psychoactive effects of cannabis, or a placebo; completion of questionnaires; and a 1-hour brain scan. One visit will also include a blood draw for genetic testing.
The 2 groups in the trial
- MalesOther group
Treatment: Dronabinol and Placebo
- FemalesOther group
Treatment: Dronabinol and Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Contribution of the Endocannabinoid System to Sex Differences in THC-associated Reward
- Fit questions
- Built from NCT07815691, who can take part
- Record updated
- 5 October 2026